25. Progressive multifocal leukoencephalopathy
23 clinical trials,   33 drugs   (DrugBank: 20 drugs),   7 drug target genes,   36 drug target pathways

Searched query = "Progressive multifocal leukoencephalopathy", "PML", "Leukoencephalopathy, progressive multifocal"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04453917
(ClinicalTrials.gov)
December 31, 20203/6/2020Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal LeukoencephalopathyDynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal LeukoencephalopathyProgressive Multifocal LeukoencephalopathyBiological: Collection of blood and urine;Biological: Spinal tap;Diagnostic Test: Brain MRI;Biological: Neurological evaluationUniversity Hospital, ToulouseNULLNot yet recruiting18 YearsN/AAll15N/AFrance
2NCT04091932
(ClinicalTrials.gov)
August 20, 201915/9/2019Treatment of PD-1 Inhibitor in AIDS-associated PMLThe Effect and Safety of Programmed Cell Death Protein 1 (PD-1) Inhibitor on AIDS Patients With Progressive Multifocal Leukoencephalopathy (PML): A One-center, Single-arm and Prospective StudyProgressive Multifocal Leukoencephalopathy;AIDSDrug: PembrolizumabFirst Affiliated Hospital of Zhejiang UniversityNULLRecruiting18 Years65 YearsAll10Phase 2China
3NCT03399981
(ClinicalTrials.gov)
January 24, 20189/1/2018Tysabri Observational Cohort Study - Multiple Sclerosis (MS) RegistriesAn Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registries to Estimate the Risk of Progressive Multifocal Leukoencephalopathy (PML) and Other Serious Opportunistic Infections Among Patients Who Were Exposed to an MS Disease Modifying Treatment Prior to Treatment With TysabriProgressive Multifocal LeukoencephalopathyBiological: TysabriBiogenNULLActive, not recruitingN/AN/AAll72600United States
4JPRN-UMIN000022151
2016/04/3030/04/2016The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathyThe efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy - The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathymefloquine is to be taken orally 275mg for 3days then 275mg weekly for 6 manthsDepartment of Neurology, Shimane University HospitalNULLComplete: follow-up complete20years-oldNot applicableMale and Female5Not selectedJapan
5JPRN-UMIN000023752
2016/04/1424/08/2016Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance progressive multifocal leukoencephalopathyOral mefloquine hydrochloride 275mg once a day at first 3 days.
Since second week, 275mg in each week oral intake until 6 months
Nagoya City UniversityNULLComplete: follow-up completeNot applicableNot applicableMale and Female1Not applicableJapan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02694783
(ClinicalTrials.gov)
March 28, 201627/2/2016Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-CellsA Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-cellsProgressive Multifocal LeukoencephalopathyBiological: PyVSTNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompleted18 YearsN/AAll60Early Phase 1United States
7NCT01970410
(ClinicalTrials.gov)
October 201322/10/2013Sub-Study: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide - SWITCH-JCVSwitching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective? (Sub-study: SWITCH-JCV)Multiple SclerosisDrug: teriflunomideProvidence Health & ServicesMultiple Sclerosis Center of Northeastern New YorkRecruiting21 Years60 YearsAll70Phase 4United States
8EUCTR2012-000725-41-GB
(EUCTR)
22/01/201304/09/2012A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal LeukoencephalopathyA randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy. - INVICTUS HIV-infected patients with Progressive Multifocal Leukoencephalopathy
MedDRA version: 15.0;Level: PT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy;System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02]
Product Name: Recombinant human interleukin-7
Product Code: CYT107
INN or Proposed INN: N/A
Other descriptive name: Recombinant human interleukin-7
Cytheris S.A.NULLNot RecruitingFemale: yes
Male: yes
57Phase 2bUnited States;European Union;Spain;Italy;Switzerland;United Kingdom
9EUCTR2012-000725-41-ES
(EUCTR)
12/12/201214/09/2012A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal LeukoencephalopathyA randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy. - INVICTUS HIV-infected patients with Progressive Multifocal Leukoencephalopathy
MedDRA version: 15.0;Level: PT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy;System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02]
Product Name: Recombinant human interleukin-7
Product Code: CYT107
INN or Proposed INN: N/A
Other descriptive name: Recombinant human interleukin-7
Cytheris S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
57Phase 2bUnited States;European Union;Spain;United Kingdom;Switzerland
10EUCTR2012-000725-41-IT
(EUCTR)
08/11/201211/12/2012A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal LeukoencephalopathyA randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy - INVICTUS HIV-infected patients with Progressive Multifocal Leukoencephalopathy
MedDRA version: 14.1;Level: SOC;Classification code 10021881;Term: Infections and infestations;System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02]
Product Name: Recombinant human interleukin-7
Product Code: CYT107
Other descriptive name: Recombinant human interleukin-7
CYTHERISNULLNot RecruitingFemale: yes
Male: yes
57Phase 2bUnited States;Spain;United Kingdom;Switzerland;Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2010-020369-26-DE
(EUCTR)
29/11/201018/08/2010High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on NatalizumabHigh-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab Immune Reconstitution Inflammatory Syndrome
MedDRA version: 12.1;Level: PT;Classification code 10054014;Term: Immune reconstitution syndrome
Product Name: methylprednisolone
INN or Proposed INN: METHYLPREDNISOLONE
Product Name: prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: prednisolone
INN or Proposed INN: PREDNISOLONE
Biogen IdecNULLNot RecruitingFemale: yes
Male: yes
20Germany
12NCT01211665
(ClinicalTrials.gov)
September 201029/7/2010Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on NatalizumabImmune Reconstitution Inflammatory Syndrome;Leukoencephalopathy, Progressive MultifocalDrug: Methylprednisolone;Drug: PrednisoloneBiogenElan PharmaceuticalsTerminated18 YearsN/AAll3Phase 4United States;Germany
13EUCTR2008-001314-24-IT
(EUCTR)
15/01/200919/03/2009A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) - NDA Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) - ND Progressive Multifocal Leukoencephalopathy (PML)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy
Trade Name: Lariam
INN or Proposed INN: Mefloquine
BIOGEN IDEC LTDNULLNot RecruitingFemale: yes
Male: yes
40United Kingdom;France;Spain;Italy
14EUCTR2008-001314-24-GB
(EUCTR)
02/01/200928/05/2008A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) Progressive Multifocal Leukoencephalopathy (PML)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy
Trade Name: Lariam
Product Name: Mefloquine
Product Code: 111JC101
INN or Proposed INN: MEFLOQUINE
Biogen Idec LtdNULLNot RecruitingFemale: yes
Male: yes
60United Kingdom;France;Spain;Italy
15NCT00746941
(ClinicalTrials.gov)
January 20093/9/2008Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML)Progressive Multifocal LeukoencephalopathyDrug: mefloquineBiogenElan PharmaceuticalsTerminated18 Years75 YearsAll37Phase 1;Phase 2United States;Brazil;Germany;Italy;Spain;Australia;France;Puerto Rico;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2008-001314-24-ES
(EUCTR)
19/11/200811/07/2008A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP) Progressive Multifocal Leukoencephalopathy (PML)Leucoencefalopatía Multifocal Progresiva (LMP)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy
Trade Name: Lariam
Product Name: Mefloquine
Product Code: 111JC101
INN or Proposed INN: MEFLOQUINE
Biogen Idec LtdNULLNot RecruitingFemale: yes
Male: yes
40United Kingdom;France;Spain;Italy
17EUCTR2008-001314-24-FR
(EUCTR)
22/10/200823/07/2008A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) Progressive Multifocal Leukoencephalopathy (PML)
MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy
Trade Name: Lariam
Product Name: Mefloquine
Product Code: 111JC101
INN or Proposed INN: MEFLOQUINE
Biogen Idec LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40United Kingdom;France;Spain;Italy
18NCT00120367
(ClinicalTrials.gov)
April 200511/7/2005Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)Early Intensification of Combination Antiretroviral Therapy Including FUZEON® in the Treatment of Progressive Multifocal Leucoencephalopathy During HIV-1 Infection ANRS 125 TrialLeukoencephalopathy, Progressive Multifocal;HIV InfectionsDrug: Enfuvirtide;Drug: Tenofovir-EmtricitabineFrench National Agency for Research on AIDS and Viral HepatitisHoffmann-La Roche;Gilead SciencesCompleted18 YearsN/ABoth30Phase 2France
19NCT00000945
(ClinicalTrials.gov)
November 19992/11/1999A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS PatientsA Pilot Study of the Effect of Cidofovir for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Subjects With Acquired Immunodeficiency Syndrome (AIDS)HIV Infections;Leukoencephalopathy, Progressive MultifocalDrug: Cidofovir;Drug: ProbenecidNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted18 YearsN/ABoth24N/AUnited States
20NCT00001048
(ClinicalTrials.gov)
February 19982/11/1999Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected PatientsA Phase II Multicenter Study Comparing Antiretroviral Therapy Alone to Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Human Immunodeficiency Virus (HIV)-Infected SubjectsHIV Infections;Leukoencephalopathy, Progressive MultifocalDrug: Filgrastim;Drug: Cytarabine;Drug: Zidovudine;Drug: Zalcitabine;Drug: DidanosineNational Institute of Allergy and Infectious Diseases (NIAID)Bristol-Myers Squibb;UpjohnCompleted18 Years65 YearsBoth90Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT00002274
(ClinicalTrials.gov)
October 19972/11/1999A Study of ddI in Patients With AIDS Who Become Sicker While Taking ZidovudineAn Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) Exhibiting Significant Deterioration While Taking Zidovudine (Retrovir)HIV Infections;Leukoencephalopathy, Progressive MultifocalDrug: DidanosineBristol-Myers SquibbNULLCompleted12 YearsN/ABothN/AUnited States
22NCT00002270
(ClinicalTrials.gov)
October 19972/11/1999A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 InfectionA Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 InfectionHIV Infections;Leukoencephalopathy, Progressive MultifocalDrug: Interferon alfa-2b;Drug: ZidovudineUniversity of MiamiNULLCompleted18 Years65 YearsBothN/AUnited States
23NCT00002395
(ClinicalTrials.gov)
June 19962/11/1999Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)An Open, Comparative Phase II Study of Immediate Versus Delayed Treatment With Topotecan HCl Given as a Continuous 21-Day Infusion Every 28 Days to Patients With AIDS-Related Progressive Multifocal LeukoencephalopathyHIV Infections;Leukoencephalopathy, Progressive MultifocalDrug: TopotecanSmithKline BeechamNULLCompleted18 YearsN/ABoth54Phase 2United States